# Extendicare Inc. (EXE.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Healthcare / Health Care Equipment & Supplies. Price C$31.10, market value C$3.0 billion.

## Valuation
- **P/E (trailing): 23.7×** (5-yr avg 22.8×, 3-yr avg 15.8×). Extendicare Inc. trades at 23.7× trailing earnings, close to its own five-year average of 22.8×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 19.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.66**. A PEG of 0.66 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.5×**. Each dollar of revenue is priced at 1.5×.
- **Price / book: 7.3×**. The shares trade at 7.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 13.8×**. Enterprise value is 13.8× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.0%** (5-yr avg -1.3%). Free cash flow equals 2.0% of the market value, above its five-year average of -1.3%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 4.2%**. The inverse of the P/E: 4.2% of the price is earned each year.

## Profitability
- **Operating margin: 8.8%**. 8.8% of revenue is left after running the business.
- **Net margin: 5.8%**. 5.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 25.9%**. 25.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 36.8%**. Return on all capital, debt included, is 36.8%: comfortably above what that capital costs.
- **Return on assets: 11.4%**. Each dollar of assets produces 11.4% of profit.

## Growth
- **Revenue growth (1 yr): 13.2%** (3-yr 10.8%/yr, 5-yr 8.5%/yr). Revenue grew 13.2% over the last year, against 8.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 29.1%** (5-yr 13.1%/yr). Earnings per share rose 29.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.92**. Debt is 0.92 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Extendicare Inc. holds more cash than debt.
- **Interest coverage: 7.3×**. Operating profit covers interest 7.3× over, a safe margin.
- **Current ratio: 1.37** (quick 1.37). Current assets cover the next year's liabilities 1.37 times.
- **Altman Z-score: 5.17**. A Z-score of 5.17 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.70%** (C$0.51 per share, trailing). Extendicare Inc. yields 1.70%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 43%** (77% of free cash flow). 43% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 11**. 11 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 0.8%/yr** (1-yr 4.2%). The dividend has grown 0.8% a year over five years.

## Price and momentum
- **Total return (1 yr): 143.9%** (YTD 47.0%, 3-mo -6.0%). The shares are up 143.9% over twelve months including dividends.
- **From 52-week high: -20.5%** (142.2% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 0.39** (volatility 35%). Beta of 0.39 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EXE.TO · Page: https://foliofundamentals.com/stocks/exe.to

Not investment advice.